Tagged with Canada

Canada Canada’s medical cannabis market is valued as a USD 1.3 billion market opportunity, with the recreational market potential worth over USD eight billion. Ontario is the Canadian state with by far the largest number of licensed cannabis producers with 57 compared to just 22 in second-placed British Colombia and seven…

Global The global regulatory landscape for medical cannabis, showing the countries in which medical cannabis and cannabinoid treatments are legal / essentially legal, illegal but often unenforced, decriminalized, and illegal.   Made with Visme Infographic Maker   Click here to download our report on Canada’s world-leading medical cannabis industry

Cannabis While many Canadian medical cannabis outfits cover the entire value chain, from research and development through to manufacturing and distribution, others – such as Canopy Health and Tetra Bio-Pharma – are taking their cues from the biotechnology industry and strictly focusing on clinical trials.   I believe that across the…

Valeant Valeant Pharmaceuticals has taken the decision to rename itself in an effort to distance the company from a series of pricing scandals that occurred under previous CEO J. Michael Pearson. Following the loss of nearly 93 percent of its value, the much maligned firm has announced that it will adopt…

Canada “If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career path, the company’s dual focus on medicinal and recreational cannabis, and how Canada will always remain the core center of…

Canada With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO Neil Closner also highlights MedReleaf’s important efforts in conducting R&D and clinical studies in order to present practitioners with relevant…

Canada Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering from rare diseases, while emphasizing the importance of an adequate rare disease framework to streamline this process in the future.…

Canada Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer Biomet positions itself as a true partner in driving efficiency in the Canadian healthcare system. 2017 was an eventful year…

Canada Looking back on 40 years of commitment to Canada, Servier also celebrates 20 years of R&D activity in the country. On this two-fold anniversary, Frédéric Fasano highlights some of the company’s more recent achievements in terms of portfolio growth and partnering efforts, while also addressing some of the challenges Servier…

Canada Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market trends in order to fuel expansion. Finally, he gives an insight into the importance of honing new skills and how…

Canada Despite its relative youth, Canada’s medical cannabis industry is already presenting some of the characteristics of the much more mature pharmaceutical industry. There is consolidation as well as the first moves towards differentiating business models. “With medical cannabis, there is a chance to re-evaluate entirely the way we look at…

Canada Susanne Picard, founder and president at SPharm, speaks about how her passion for regulatory affairs led her to found her own consultancy in 1997 and how the company can look back at an impressive track record of success over the last 21 years. Here, she outlines key priorities to further…